These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.
What does FDA’s record show, in brief?
| Facility | Imprimis NJOF, LLC |
| Location | Ledgewood, New Jersey |
| Type | 503B outsourcing facility |
| Registered since | November 12, 2016 |
| Latest registration | November 26, 2025 |
| Last FDA inspection | August 18, 2026 |
| Inspection dates | 08/04/2026 to 08/18/2026 |
| Form 483 | Issued, 6 observations |
| FDA action after the inspection | Open |
| Compounds sterile drugs from bulk | Yes |
| FDA warning letters on GLP-1 drugs | 0 |
What did FDA’s investigators observe?
The Form 483 from the inspection of 08/18/2026 lists 6 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2
| What the observation is about | Observations |
|---|---|
| Sterility and aseptic processing | 2 |
| Written procedures and quality unit | 1 |
| Testing and release of batches | 1 |
FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.
Has this facility recalled any drugs?
FDA’s enforcement reports list 21 recalled products from this facility, from December 17, 2020 to December 18, 2025: 14 in Class II, 7 in Class III. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3
| Started | Class | Product | Reason |
|---|---|---|---|
| 2025-12-18 | II | Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL | Presence of particulate matter - Glass like particles. |
| 2025-12-18 | II | Dexamethasone Moxifloxacin Ketorolac | Presence of particulate matter - Glass like particles. |
| 2025-12-18 | II | Dexamethasone Moxifloxacin | Presence of particulate matter - Glass like particles. |
| 2025-10-20 | III | Klarity-C Drops (Cyclosporine) 0.1% | Subpotent Drug |
| 2025-07-09 | III | Tropicamide-Proparacaine-Phenylephrine-Ketorolac | Sub-Potent Drug: Subpotent assay results during stability testing. |
| 2025-07-09 | II | Epinephrine Lidocaine HCL | Sub-Potent Drug: Subpotent assay results during stability testing. |
| 2025-02-24 | III | Tropicamide - Proparacaine - Phenylephrine - Ketorolac Sterile Ophthal | Sub-Potent Drug: The stability batch showed a subpotent result, which does not meet the product specifications of 90.0-1… |
| 2024-05-14 | II | Prednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic Suspension | Lack of Assurance of Sterility |
The table shows 8 of the 21 recalls; the rest are in FDA’s enforcement reports.
Is the pharmacy behind my prescription on FDA’s list?
Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.
Where are the registered outsourcing facilities?
8 of the 100 facilities on FDA’s list are in New Jersey. The chart counts them by state; choose a view to see which ones FDA has inspected.
Which other facilities are in the same state?
What does it mean that a pharmacy is a 503B outsourcing facility?
An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1
A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.
Sources
- FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
- FDA. Form FDA 483, inspection of Imprimis NJOF, LLC, 08/04/2026 to 08/18/2026. fda.gov
- FDA. Drug recall enforcement reports for Imprimis NJOF, LLC, read through openFDA on November 20, 2026. open.fda.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider